Announcement on Change of Financial Officer and Acting Spokesperson

Subsidiary AP Biosciences and Tasly Biopharmaceuticals Signed Cooperative Development and Authorized Agreement of New Antibody Drug
July 29, 2019
IND Phase I/II Human Clinical Trial Application of Globo-H Antibody-Drug Conjugate, OBI-999, submission to FDA
August 3, 2019
  1. Type of personnel changed (please enter: spokesperson, acting
    spokesperson, important operational officer, financial officer,
    accounting officer, company secretary, research and development
    officer, or internal audit officer): Financial officer and acting spokesperson
  2. Date of occurrence of the change: Jul 31, 2019
  3. Name, title, and resume of the replaced person: Max Chan, Chief Financial Officer
  4. Name, title, and resume of the replacement:
    Financial Officer: Frank Chen, Board member and chief financial officer (Temporally)
    Acting Spokesperson: Ming-Tain Lai, R&D Executive Vice President (Temporally)
  5. Type of the change (please enter: “resignation”, “position adjustment”, “dismissal”, “retirement”, “death” or “new replacement” ): Resignation
  6. Reason for the change: Personal career plan
  7. Effective date: Jul 31, 2019
  8. Contact telephone number of the replacement: (02)2655-8799
  9. Any other matters that need to be specified: Frank Chen and Ming-Tain Lai will temporally take over responsibilities of financial officer and acting spokesperson, respectively until Board of Directors make the final decision.